Candel Therapeutics Inc. (NASDAQ: CADL) will present phase 3 clinical trial results for its experimental treatment CAN-2409 in localized prostate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE